Why Heart Transplant Patients Sometimes Get the Wrong Dose of Anti-Rejection Drugs

Roughly 40% of heart transplant recipients reject their organ within the first year, and a new study argues the diagnostic tool clinicians rely on most, the microscope-based rejection grade assigned to an endomyocardial biopsy, is too coarse to tell doctors how aggressively to treat each of them.

In a paper published in Nature Cardiovascular Research, a Vanderbilt Health and Translational Genomics Research Institute (TGen) team used image-based spatial transcriptomics (gene activity maps at subcellular resolution across intact tissue) to profile biopsy samples from 62 adult and pediatric heart transplant recipients, collected longitudinally during and after histologically diagnosed rejection. The team identified 28 cell types whose transcriptional states varied across rejection classes.

The team found broad overlap in the transcriptional programs seen across rejection severity, but substantial molecular heterogeneity within grades. Two biopsies that earn the same microscope score can carry different biological signatures, and plausibly call for different doses of immunosuppressive therapy.

"Clinical presentation varies dramatically within the same grade of histologic rejection, and response to antirejection therapy is heterogeneous, including lack of response in some patients," co-senior author Ravic Shah, a cardiologist at Vanderbilt Health, told GEN. The team's stated translational aim is to use that molecular read-out to sharpen diagnosis, predict treatment response, and stratify long-term risk after transplantation.

The authors' named consequence of that mismatch is over- or under-immunosuppression, with graft failure and death as the long-term tail risks in patients whose disease is misread. Today's biopsy-based grading still uses the same microscope score clinicians have applied for decades. A Medical Xpress summary of the work frames the gap between grade and clinical course as the central problem the new map is meant to address.

The study is not yet a clinical test. The authors describe the work as a molecular finding and a translational program; independent validation in a separate cohort, the turnaround time and cost of running a spatial transcriptomics panel in a clinical lab, and a head-to-head comparison with existing molecular rejection diagnostics (gene-expression panels such as AlloMap and donor-derived cell-free DNA) all sit ahead of it. The paper's cohort of 62 recipients, including children, is large for a spatial transcriptomics study but small by the standards of a deployed diagnostic, and the within-grade heterogeneity the team documents is qualitative until effect sizes are quantified in replication.

The next test is whether the molecular substructure inside a single grade is reproducible and large enough to guide dosing. A head-to-head comparison with AlloMap and donor-derived cell-free DNA, plus a workable turnaround time and cost in a clinical lab, will decide whether the new map reaches the clinic.